Filtered By:
Specialty: Dermatology
This page shows you your search results in order of date.
Order by Relevance | Date
Total 248 results found since Jan 2013.
Narrowband Intense Pulsed Light Treatment for Refractory Facial Rash Associated with Dermatomyositis
We present a case of cutaneous dermatomyositis that was successfully treated with narrowband intense pulsed light.PMID:37719932 | PMC:PMC10504899 | DOI:10.2147/CCID.S426762
Source: Clinical, Cosmetic and Investigational Dermatology - September 18, 2023 Category: Dermatology Authors: Yuxin Zheng Suiqing Cai Source Type: research
Pyomyositis Secondary to Localized Cellulitis in a Dermatomyositis Patient: A Case Report and Review of Infectious Complications in Dermatomyositis
Clin Cosmet Investig Dermatol. 2023 Aug 11;16:2201-2209. doi: 10.2147/CCID.S417772. eCollection 2023.ABSTRACTDermatomyositis (DM) is an autoimmune disorder characterized by proximal muscle weakness and distinct cutaneous features. Unfortunately, infection is a frequent and potentially life-threatening complication in patients with DM. Here, we present a case of pyomyositis in a patient with DM resulting from localized cellulitis. The patient also presented with subcutaneous calcification nodules and dermatomyositis-associated lipodermatosclerosis nodules. To our knowledge, there have been no reports of pyomyositis in patie...
Source: Clinical, Cosmetic and Investigational Dermatology - August 17, 2023 Category: Dermatology Authors: Xingwei Zhang Xiaoyan Lyu Source Type: research
Amyopathic dermatomyositis with TIF1? positivity treated with IVIG
We present a patient with anti-TIF1? positive amyopathic dermatomyositis associated with bilateral breast cancer. The patient was safely treated with trastuzumab for breast cancer and intravenous immunoglobulin for dermatomyositis.PMID:37220289 | DOI:10.5070/D329260773
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Simon W Jiang Jeffery T Kwock Anne L Marano Source Type: research
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.ABSTRACTDermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, l...
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Miguel Esperanca-Martins Sara Damaso Nuno Carreira Barbara Pena Catarina Correia Marta Aguado-Lobo Pablo Espinosa-Lara Luis Soares-de-Almeida Leonor Abreu Ribeiro Luis Costa Source Type: research
Amyopathic dermatomyositis with TIF1? positivity treated with IVIG
We present a patient with anti-TIF1? positive amyopathic dermatomyositis associated with bilateral breast cancer. The patient was safely treated with trastuzumab for breast cancer and intravenous immunoglobulin for dermatomyositis.PMID:37220289 | DOI:10.5070/D329260773
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Simon W Jiang Jeffery T Kwock Anne L Marano Source Type: research
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.ABSTRACTDermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, l...
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Miguel Esperanca-Martins Sara Damaso Nuno Carreira Barbara Pena Catarina Correia Marta Aguado-Lobo Pablo Espinosa-Lara Luis Soares-de-Almeida Leonor Abreu Ribeiro Luis Costa Source Type: research
Amyopathic dermatomyositis with TIF1? positivity treated with IVIG
We present a patient with anti-TIF1? positive amyopathic dermatomyositis associated with bilateral breast cancer. The patient was safely treated with trastuzumab for breast cancer and intravenous immunoglobulin for dermatomyositis.PMID:37220289 | DOI:10.5070/D329260773
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Simon W Jiang Jeffery T Kwock Anne L Marano Source Type: research
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.ABSTRACTDermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, l...
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Miguel Esperanca-Martins Sara Damaso Nuno Carreira Barbara Pena Catarina Correia Marta Aguado-Lobo Pablo Espinosa-Lara Luis Soares-de-Almeida Leonor Abreu Ribeiro Luis Costa Source Type: research
Amyopathic dermatomyositis with TIF1? positivity treated with IVIG
We present a patient with anti-TIF1? positive amyopathic dermatomyositis associated with bilateral breast cancer. The patient was safely treated with trastuzumab for breast cancer and intravenous immunoglobulin for dermatomyositis.PMID:37220289 | DOI:10.5070/D329260773
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Simon W Jiang Jeffery T Kwock Anne L Marano Source Type: research
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.ABSTRACTDermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, l...
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Miguel Esperanca-Martins Sara Damaso Nuno Carreira Barbara Pena Catarina Correia Marta Aguado-Lobo Pablo Espinosa-Lara Luis Soares-de-Almeida Leonor Abreu Ribeiro Luis Costa Source Type: research
Amyopathic dermatomyositis with TIF1? positivity treated with IVIG
We present a patient with anti-TIF1? positive amyopathic dermatomyositis associated with bilateral breast cancer. The patient was safely treated with trastuzumab for breast cancer and intravenous immunoglobulin for dermatomyositis.PMID:37220289 | DOI:10.5070/D329260773
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Simon W Jiang Jeffery T Kwock Anne L Marano Source Type: research
Paraneoplastic or treatment-associated dermatomyositis: a diagnostic challenge
Dermatol Online J. 2023 Apr 15;29(2). doi: 10.5070/D329260768.ABSTRACTDermatomyositis (DM) is a systemic autoimmune disorder characterized by proximal myopathy and dermatological findings. Approximately 15-30% of DM cases emerge as a paraneoplastic syndrome caused by a concomitant malignancy. Although more rare, in cancer patients DM has also been reported as a possible result of toxicity of some antineoplastic agents, such as taxanes and monoclonal antibodies. Herein, we report a 35-year-old woman with metastatic breast cancer who presented with skin lesions after initiation of paclitaxel and anti-HER2 agents. Clinical, l...
Source: Dermatol Online J - May 23, 2023 Category: Dermatology Authors: Miguel Esperanca-Martins Sara Damaso Nuno Carreira Barbara Pena Catarina Correia Marta Aguado-Lobo Pablo Espinosa-Lara Luis Soares-de-Almeida Leonor Abreu Ribeiro Luis Costa Source Type: research
